Akebia Therapeutics, Inc. Stock

$3.93

1.26%

Nasdaq, Jul 11, 10:07 pm CET

ISIN

US00972D1054

Symbol

AKBA

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Akebia Therapeutics, Inc. Stock price

$3.93

-7.90 66.78% 5Y

Nasdaq, Closing price Fri, Jul 11 2025

-0.05 1.26%

ISIN

US00972D1054

Symbol

AKBA

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$1.0b

Enterprise Value

$965.3m

Net debt

positive

Cash

$113.4m

Shares outstanding

261.6m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

5.6 | 5.1

EV/Sales

5.2 | 4.7

EV/FCF

negative

P/B

42.0

Financial Health

Equity Ratio

-22.3%

Return on Equity

141.1%

ROCE

-8.3%

ROIC

Debt/Equity

1.9

Financials (TTM | estimate)

Revenue

$184.9m | $203.2m

EBITDA

$8.8m | -

EBIT

$-18.2m | $-8.9m

Net Income

$-45.3m | $-17.1m

Free Cash Flow

$-34.9m

Growth (TTM | estimate)

Revenue

-1.2% | 26.9%

EBITDA

479.6% | -

EBIT

47.2% | 80.8%

Net Income

-5.2% | 75.4%

Free Cash Flow

-37.9%

EPS

$-0.2

FCF per Share

$-0.1

Short interest

7.1%

Employees

181

Rev per Employee

$880.0k

As a Free StocksGuide user, you can view scores for all 7,006 stocks worldwide.

Get Started for Free Today

Akebia Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

??

11 Analysts have issued a Akebia Therapeutics, Inc. forecast:

10x Buy

91%

More details on Analyst Estimates Including Price Targets

11 Analysts have issued a Akebia Therapeutics, Inc. forecast:

Buy

91%

Hold

Analyst Estimates with Stock Price Targets

Financial data from Akebia Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	185 185	1% 1% 100%
- Direct Costs	32 32	1% 1% 17%
Gross Profit	153 153	1% 1% 83%
- Selling and Administrative Expenses	107 107	6% 6% 58%
- Research and Development Expense	38 38	29% 29% 20%
EBITDA	8.81 8.81	480% 480% 5%
- Depreciation and Amortization	27 27	25% 25% 15%
EBIT (Operating Income) EBIT	-18 -18	47% 47% -10%
Net Profit	-45 -45	5% 5% -25%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Akebia Therapeutics, Inc. Stock News

Neutral

GlobeNewsWire

●

6 days ago

Akebia Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference

CAMBRIDGE, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that Nik Grund, Chief Commercial Officer, will participate in a Fireside Chat at the H.C.

Neutral

GlobeNewsWire

●

13 days ago

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., July 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted four newly-hired employees options to purchase an aggregate of 141,800 shares of Akebia's common stock on June 30, 2025. The options were granted as an inducement material to each employee ...

Neutral

GlobeNewsWire

●

about one month ago

Vadadustat U.S. Patient Data from Global Phase 3 Clinical Program Published in Journal of the American Society of Nephrology

Akebia continues to publish important, clinically relevant data to further physicians' understanding of Vafseo® (vadadustat) Akebia continues to publish important, clinically relevant data to further physicians' understanding of Vafseo® (vadadustat)

More Akebia Therapeutics, Inc. News

Company Profile

Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney disease. The firm also involves in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.

Head office	United States
CEO	John Butler
Employees	181
Founded	2007
Website	akebia.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now